Guidance

Meningococcal disease enhanced surveillance plan

The national surveillance protocol for invasive meningococcal disease in England

Documents

Meningococcal disease enhanced surveillance plan

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Meningococcal disease surveillance flow chart

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail

The national surveillance protocol for invasive meningococcal disease (IMD) in England has been extended in recognition of:

  • changes to the meningococcal group C conjugate (MCC) vaccination programme, including the removal of the infant MCC dose at 4 months and the introduction of an adolescent MCC dose in June 2013
  • the emergency introduction of a quadrivalent conjugate vaccine against meningococcal groups A, C, W, and Y (MenACWY) for 14 to 18 year olds in August 2015 in response to a national outbreak of a hypervirulent MenW
  • the introduction of a MenB vaccine, Bexsero®, into the national infant immunisation schedule in September

The Meningococcal disease enhanced surveillance plan flowchart has been compiled to summarise and clarify the actions required by Public Health England health protection teams following the report of a suspected case of invasive meningococcal disease.

Record suspected or confirmed cases of invasive meningococcal disease using the enhanced surveillance forms for healthcare professionals.